PURPOSE: The receptors for hepatocyte and vascular endothelial cell growth factors (MET and VEGFR2, respectively) are critical oncogenic mediators in gastric adenocarcinoma. The purpose is to examine the safety and efficacy of foretinib, an oral multikinase inhibitor targeting MET, RON, AXL, TIE-2, and VEGFR2 receptors, for the treatment of metastatic gastric adenocarcinoma. PATIENTS AND METHODS: Foretinib safety and tolerability, and objective response rate (ORR) were evaluated in patients using intermittent (240 mg/day, for 5 days every 2 weeks) or daily (80 mg/day) dosing schedules. Thirty evaluable patients were required to achieve alpha = 0.10 and beta = 0.2 to test the alternative hypothesis that single-agent foretinib would result in an ORR of ≥ 25%. Up to 10 additional patients could be enrolled to ensure at least eight with MET amplification. Correlative studies included tumor MET amplification, MET signaling, pharmacokinetics and plasma biomarkers of foretinib activity. RESULTS: From March 2007 until October 2009, 74 patients were enrolled; 74% male; median age, 61 years (range, 25-88); 93% had received prior therapy. Best response was stable disease (SD) in 10 (23%) patients receiving intermittent dosing and five (20%) receiving daily dosing; SD duration was 1.9-7.2 months (median 3.2 months). Of 67 patients with tumor samples, 3 had MET amplification, one of whom had SD. Treatment-related adverse events occurred in 91% of patients. Rates of hypertension (35% vs. 15%) and elevated aspartate aminotransferase (23% vs. 8%) were higher with intermittent dosing. In both patients with high baseline tumor phospho-MET (pMET), the pMET:total MET protein ratio decreased with foretinib treatment. CONCLUSION: These results indicate that few gastric carcinomas are driven solely by MET and VEGFR2, and underscore the diverse molecular oncogenesis of this disease. Despite evidence of MET inhibition by foretinib, single-agent foretinib lacked efficacy in unselected patients with metastatic gastric cancer.
PURPOSE: The receptors for hepatocyte and vascular endothelial cell growth factors (MET and VEGFR2, respectively) are critical oncogenic mediators in gastric adenocarcinoma. The purpose is to examine the safety and efficacy of foretinib, an oral multikinase inhibitor targeting MET, RON, AXL, TIE-2, and VEGFR2 receptors, for the treatment of metastatic gastric adenocarcinoma. PATIENTS AND METHODS: Foretinib safety and tolerability, and objective response rate (ORR) were evaluated in patients using intermittent (240 mg/day, for 5 days every 2 weeks) or daily (80 mg/day) dosing schedules. Thirty evaluable patients were required to achieve alpha = 0.10 and beta = 0.2 to test the alternative hypothesis that single-agent foretinib would result in an ORR of ≥ 25%. Up to 10 additional patients could be enrolled to ensure at least eight with MET amplification. Correlative studies included tumor MET amplification, MET signaling, pharmacokinetics and plasma biomarkers of foretinib activity. RESULTS: From March 2007 until October 2009, 74 patients were enrolled; 74% male; median age, 61 years (range, 25-88); 93% had received prior therapy. Best response was stable disease (SD) in 10 (23%) patients receiving intermittent dosing and five (20%) receiving daily dosing; SD duration was 1.9-7.2 months (median 3.2 months). Of 67 patients with tumor samples, 3 had MET amplification, one of whom had SD. Treatment-related adverse events occurred in 91% of patients. Rates of hypertension (35% vs. 15%) and elevated aspartate aminotransferase (23% vs. 8%) were higher with intermittent dosing. In both patients with high baseline tumor phospho-MET (pMET), the pMET:total MET protein ratio decreased with foretinib treatment. CONCLUSION: These results indicate that few gastric carcinomas are driven solely by MET and VEGFR2, and underscore the diverse molecular oncogenesis of this disease. Despite evidence of MET inhibition by foretinib, single-agent foretinib lacked efficacy in unselected patients with metastatic gastric cancer.
Authors: Joseph Paul Eder; Geoffrey I Shapiro; Leonard J Appleman; Andrew X Zhu; Dale Miles; Harold Keer; Belinda Cancilla; Felix Chu; Suzanne Hitchcock-Bryan; Laurie Sherman; Stewart McCallum; Elisabeth I Heath; Scott A Boerner; Patricia M LoRusso Journal: Clin Cancer Res Date: 2010-05-14 Impact factor: 12.531
Authors: C Sakakura; T Mori; T Sakabe; Y Ariyama; T Shinomiya; K Date; A Hagiwara; T Yamaguchi; T Takahashi; Y Nakamura; T Abe; J Inazawa Journal: Genes Chromosomes Cancer Date: 1999-04 Impact factor: 5.006
Authors: Virna Cepero; J Rafael Sierra; Simona Corso; Elena Ghiso; Laura Casorzo; Tim Perera; Paolo Maria Comoglio; Silvia Giordano Journal: Cancer Res Date: 2010-09-14 Impact factor: 12.701
Authors: Gromoslaw A Smolen; Raffaella Sordella; Beth Muir; Gayatry Mohapatra; Anne Barmettler; Heidi Archibald; Woo J Kim; Ross A Okimoto; Daphne W Bell; Dennis C Sgroi; James G Christensen; Jeffrey Settleman; Daniel A Haber Journal: Proc Natl Acad Sci U S A Date: 2006-02-06 Impact factor: 11.205
Authors: Fawn Qian; Stefan Engst; Kyoko Yamaguchi; Peiwen Yu; Kwang-Ai Won; Lillian Mock; Tracy Lou; Jenny Tan; Connie Li; Danny Tam; Julie Lougheed; F Michael Yakes; Frauke Bentzien; Wei Xu; Tal Zaks; Richard Wooster; Joel Greshock; Alison H Joly Journal: Cancer Res Date: 2009-10-06 Impact factor: 12.701
Authors: Samuel E Deprimo; Carlo L Bello; John Smeraglia; Charles M Baum; Dominic Spinella; Brian I Rini; M Dror Michaelson; Robert J Motzer Journal: J Transl Med Date: 2007-07-02 Impact factor: 5.531
Authors: I-K Park; B Mundy-Bosse; S P Whitman; X Zhang; S L Warner; D J Bearss; W Blum; G Marcucci; M A Caligiuri Journal: Leukemia Date: 2015-06-19 Impact factor: 11.528